Using MRI to predict tumor infiltration in soft tissue and bone cancers
Official title: Development of a Radiomics Model With 3T Multiparametric MR to Predict the Occurence of a Perilesional Infiltration of Muscoskeletal Tumor During the Pre- Surgery Planning
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06774729 · Data updated 2026-11-12
This study is testing if special MRI scans can help doctors better identify tumor spread in patients suspected of having soft tissue sarcoma or bone cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 122 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | March 2025 |
| Main results expected | September 2028 |
| Study ends | October 2028 |
| Registry record updated | January 14, 2025 |
| Trial ID | NCT06774729 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who are suspected of having soft tissue sarcoma or bone cancer and are indicated for surgical treatment.
✕Probably not a fit
Patients with a history of cancer in the last 5 years or those with serious conditions that contraindicate MRI will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the feasibility and clinical utility of radiomics in diagnosing peri-lesion tumor infiltration in patients suspected of having soft tissue sarcoma or bone cancer. Participants will undergo MRI scans as part of their routine medical care, with their data being recorded and analyzed anonymously. The study seeks to determine the accuracy of radiomics in identifying true positive and negative diagnoses among participants. By leveraging advanced imaging techniques, the study hopes to enhance diagnostic capabilities for these serious conditions.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing tumor infiltration, leading to better treatment planning for patients with soft tissue sarcoma and bone cancer.
How similar studies have gone: While the use of radiomics in oncology is an emerging field, similar studies have shown promising results in enhancing diagnostic accuracy for various cancers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 * suspect of soft tissue sarcoma with a indication for surgical treatment * suspect of bone cancer tumor with a indication for surgical treatment * To give informed consent Exclusion Criteria: * simultaneous cancer or history of cancer in the last 5 years * acute or chronic serious conditions that could * contraindication to conduct a Contrast-enhanced magnetic resonance imaging (MRI) such as: * renal failure without dialysis * history of allergy to a paramagnetic contrast agent * claustrophobia * symptomatic epilepsy or history of epilepsy * cardiac pacemaker * infusion pump, prosthesis or any implant not compatible with MRI * pregnancy
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Study coordinator: Vincenzo Lucidi, MD
- Email: vincenzo.lucidi@aosp.bo.it
- Phone: +39 3385246923
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Strasbourg pST soft tissue sarcoma care patterns and survival
This study looks back at how closely soft tissue sarcoma care in Strasbourg followed international guidelines and whether that related to overall survival, comparing patient care from 2010-2016 to 2017-2024.
-
Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma
This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.
-
AYA Sarcoma Survivors: Personalized Exercise Program Pilot
This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.
-
Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma
This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors
This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.